Bartley Gill
Internal Medicine · Sugar Land, TXNPI 1346669066
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $156,275 of the $218,094 with a category attached, or 71.7%. Lilly USA, LLC accounts for 79.1% of it on its own, with 37 other manufacturers making up the rest. Among internal medicine clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,245 payments — averaging $175.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$172K
- E.r. Squibb & Sons, L.L.C.$10K
- Journey Medical Corporation$7K
- Sanofi$6K
- AbbVie$4K
- Arcutis Biotherapeutics, Inc.$4K
- plus $15K from 32 others
Across 97 payments — averaging $7669.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$432K
- Eli Lilly$207K
- Pfizer$89K
- Novartis$16K
What the payments were for
- Consulting fees$24,28411%
- Speaking & faculty fees$156,27572%
- Travel & lodging$11,4345%
- Food & beverage$25,78712%
- Education$3150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 346 | $172,437 |
| E.r. Squibb & Sons, L.L.C. | 39 | $10,204 |
| Journey Medical Corporation | 37 | $7,071 |
| Sanofi | 45 | $5,897 |
| AbbVie | 191 | $3,934 |
| Arcutis Biotherapeutics, Inc. | 39 | $3,678 |
| Novartis | 108 | $2,491 |
| Eli Lilly | 3 | $1,989 |
| Johnson & Johnson | 75 | $1,798 |
| Regeneron Healthcare Solutions, Inc. | 68 | $1,603 |
| Bristol Myers Squibb | 14 | $1,061 |
| UCB, Inc. | 24 | $1,055 |
| Amgen | 50 | $806 |
| Sun Pharmaceutical Industries Inc. | 34 | $735 |
| Incyte Corporation | 36 | $732 |
| LEO Pharma Inc. | 24 | $583 |
| Pfizer | 29 | $498 |
| Galderma Laboratories, L.p. | 20 | $407 |
| Dermavant Sciences, Inc. | 19 | $351 |
| VYNE Pharmaceuticals Inc. | 6 | $89 |
| Boehringer Ingelheim | 3 | $86 |
| Biofrontera Inc. | 5 | $76 |
| Almirall LLC | 4 | $73 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 4 | $67 |
| Organon | 6 | $60 |
| EPI Health, LLC | 2 | $40 |
| Verrica Pharmaceuticals Inc. | 2 | $39 |
| Convatec Inc. | 1 | $32 |
| Dermira, Inc. | 2 | $26 |
| Janssen Scientific Affairs, LLC | 1 | $26 |
| Medimetriks Pharmaceuticals, Inc. | 1 | $24 |
| Genentech USA, Inc. | 1 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Kyowa Kirin, Inc. | 1 | $19 |
| Botanix SB Inc | 1 | $17 |
| Mayne Pharma Commercial LLC | 1 | $16 |
| LNHC, Inc | 1 | $14 |
| Mylan Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$218,094 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 17 | $347,259 |
| Dupixent PenDupilumab | 79 | $325,708 |
| OtezlaApremilast | 32 | $157,412 |
| Taltz AutoinjectorIxekizumab | 21 | $145,473 |
| Taltz SyringeIxekizumab | 11 | $78,355 |
| Humira(Cf) PenAdalimumab | 11 | $75,155 |
| Dupixent SyringeDupilumab | 12 | $44,672 |
| Clobetasol Propionate | 229 | $12,796 |
| Tacrolimus | 40 | $6,588 |
| Halobetasol Propionate | 98 | $5,921 |
| Triamcinolone Acetonide | 328 | $2,810 |
| Ketoconazole | 140 | $2,003 |
| Doxycycline Monohydrate | 76 | $1,769 |
| Clindamycin Phosphate | 62 | $1,600 |
| Spironolactone | 52 | $1,599 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $806 | $157,41232 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Sugar Land
- Spencer BerthelsenSugar Land$891K
- Hameed AliTemple$773K
- Marc TribbleDallas$693K
- Gary SinclairDallas$599K
- Mohammed Al-NajjarEl Paso$586K
- Han SchmidlyDallas$465K
- Hussein TawbiHouston$365K
- Hans LeeHouston$327K
- Tapan KadiaHouston$311K
- Nitin JainHouston$281K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.